Castle Biosciences Inc (NASDAQ: CSTL)

Castle Biosciences, Inc. is a molecular diagnostics company that develops and commercializes proprietary gene expression profile and spatialomics tests to help clinicians diagnose and manage dermatologic cancers, Barrett’s esophagus, atopic dermatitis, and uveal melanoma. The company’s core technology uses multi analyte assays with algorithmic analysis to convert tumor or tissue biology into clinically actionable risk scores. Founded in 2008, Castle Biosciences focuses on delivering personalized information that informs treatment decisions and aims to improve patient outcomes across its test portfolio.

Castle Biosciences generates revenue primarily from the sale of its diagnostic tests, which are billed to third party payors including Medicare, commercial insurers, and patients who self pay. Reimbursement amounts are determined by Medicare clinical laboratory fee schedule rates or negotiated contracts with commercial payors, and the company also receives payments from laboratory services intermediaries. The volume of test reports delivered drives top line growth, as demonstrated by increasing test counts and net revenues in recent fiscal years.

• no_segments_reported.

Within the molecular diagnostics arena, Castle Biosciences holds a differentiated position through its portfolio of proprietary tests that have earned Medicare coverage and Advanced Diagnostic Laboratory Test status from the Centers for Medicare & Medicaid Services. The company’s competitive advantages include its strong clinical evidence base, with over 150 peer reviewed publications supporting its tests, and its ability to secure reimbursement from governmental and commercial payors. Principal competitors vary by test: for DecisionDx‑Melanoma, traditional pathology staging criteria and emerging players such as SkylineDx represent the main alternatives; for TissueCypher, standard Barrett’s esophagus surveillance and companies like Interpace Diagnostics and Lucid Diagnostics are comparable; DecisionDx‑SCC faces conventional high‑risk squamous cell carcinoma criteria; DecisionDx‑UM competes with existing ocular melanoma assays offered by academic laboratories and a LabCorp subsidiary; and MyPath Melanoma contends with subjective histologic evaluation of ambiguous pigmented lesions. The company’s focus on algorithmic driven reports, broad payer coverage, and ongoing pipeline development underpins its market stance.

Castle Biosciences serves clinicians specializing in dermatology, gastroenterology, ophthalmology, and allergy/immunology who order its tests to guide treatment decisions for patients with melanoma, squamous cell carcinoma, Barrett’s esophagus, atopic dermatitis, and uveal melanoma. The customer base includes community dermatology practices, academic medical centers, hospital based pathology laboratories, and gastroenterology clinics that send tissue or non invasive samples for analysis. While specific customer names are not disclosed in the filing, the company’s reimbursement data indicate a broad mix of Medicare beneficiaries and commercially insured individuals across the United States.